Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 200 of 1150 drug-target rows in SSL view, for TSG = BRCA1.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib BRCA1 PARP1 1
olaparib BRCA1 PARP2 1
sunitinib BRCA1 PDGFRA 7
sunitinib BRCA1 FLT3 7
sunitinib BRCA1 KDR 7
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BRCA1 PDGFRA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BRCA1 VEGFA 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab BRCA1 KDR 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) BRCA1 PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) BRCA1 KDR 4
gemcitabine BRCA1 RRM1 7
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine BRCA1 VEGFA 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine BRCA1 RRM1 3
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine BRCA1 KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 WEE1 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 PDGFRA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 CDK6 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 KDR 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 CDK4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 PIK3CA 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib BRCA1 PIK3CB 3
bevacizumab BRCA1 VEGFA 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus BRCA1 MTOR 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan BRCA1 TOP1 3
lurbinectedin, irinotecan BRCA1 TOP1 3
pembrolizumab, belzutifan, lenvatinib BRCA1 PDGFRA 3
pembrolizumab, belzutifan, lenvatinib BRCA1 KDR 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab BRCA1 RRM1 3
abemaciclib BRCA1 CDK6 7
abemaciclib BRCA1 CDK4 7
cabozantinib BRCA1 KDR 7
everolimus BRCA1 MTOR 7
nintedanib BRCA1 PDGFRA 7
nintedanib BRCA1 KDR 7
palbociclib BRCA1 CDK6 7
palbociclib BRCA1 CDK4 7
pazopanib BRCA1 PDGFRA 7
pazopanib BRCA1 KDR 7
regorafenib BRCA1 PDGFRA 7
regorafenib BRCA1 KDR 7
sacituzumab govitecan BRCA1 TOP1 7
topotecan BRCA1 TOP1 7
trastuzumab deruxtecan BRCA1 TOP1 5
ramucirumab BRCA1 KDR 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin BRCA1 VEGFA 2
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin BRCA1 RRM1 2
5fu, nab-paclitaxel, bevacizumab, calcium leucovorin, oxaliplatin BRCA1 VEGFA 2
adavosertib, radiation therapy BRCA1 WEE1 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel BRCA1 FLT3 2
alvocidib, paclitaxel BRCA1 CDK6 2
alvocidib, paclitaxel BRCA1 CDK2 2
alvocidib, paclitaxel BRCA1 CDK4 2
alvocidib, paclitaxel BRCA1 CDK5 2
antineoplastic vaccine, sargramostim, pembrolizumab BRCA1 SDC2 2
apatinib, irinotecan BRCA1 TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BRCA1 TOP1 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan BRCA1 KDR 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine BRCA1 TOP1 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine BRCA1 RRM1 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 BRCA1 KDR 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment BRCA1 VEGFA 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis BRCA1 VEGFA 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib BRCA1 CDK6 2
binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib BRCA1 CDK4 2
bryostatin 1, paclitaxel BRCA1 CASP8 2
cabozantinib, atezolizumab, cabozantinib, cabozantinib BRCA1 KDR 2
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy BRCA1 CA3 2
cetuximab, cisplatin, irinotecan, radiation therapy, surgery BRCA1 TOP1 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab BRCA1 RRM1 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study BRCA1 MTOR 2
cpt- 11, cisplatin, celecoxib, radiation, surgery BRCA1 CA3 2
cyclophosphamide, neoantigen peptide vaccine, pembrolizumab, sargramostim BRCA1 SDC2 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab BRCA1 CDK6 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab BRCA1 CDK4 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib BRCA1 FLT3 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib BRCA1 KDR 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study BRCA1 HDAC2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a BRCA1 PDGFRA 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a BRCA1 KDR 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide BRCA1 TOP1 2
irinotecan, capecitabine BRCA1 TOP1 2
irinotecan, docetaxel BRCA1 TOP1 2
ksq-001ex, interleukin-2, cyclophosphamide, fludarabine BRCA1 RRM1 2
lenvatinib, pembrolizumab BRCA1 PDGFRA 2
lenvatinib, pembrolizumab BRCA1 KDR 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate BRCA1 PDGFRA 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate BRCA1 KDR 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab BRCA1 TOP1 2
ly4066434., cetuximab, nab paclitaxel, gemcitabine, oxaliplatin, leucovorin, irinotecan, 5fluorouracil, carboplatin, cisplatin, pemetrexed, pembrolizumab BRCA1 RRM1 2
melphalan, bcnu, vitamin b12b, vitamin c, ethanol, autologous hematopoietic stem cells BRCA1 HTR3C 2
mk-0482, pembrolizumab, paclitaxel, nab-paclitaxel, gemcitabine, carboplatin, pemetrexed BRCA1 RRM1 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a BRCA1 PDGFRA 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a BRCA1 KDR 2
nab-paclitaxel, gemcitabine BRCA1 RRM1 2
nintedanib BRCA1 FLT3 2
nintedanib, pembrolizumab BRCA1 PDGFRA 2
nintedanib, pembrolizumab BRCA1 FLT3 2
nintedanib, pembrolizumab BRCA1 KDR 2
olaparib BRCA1 PARP3 2
oleclumab, durvalumab, gemcitabine, nab-paclitaxel, oxaliplatin, folinic acid, 5-fu BRCA1 RRM1 2
osimertinib, bevacizumab, osimertinib BRCA1 VEGFA 2
pd-1 inhibitor, bevacizumab, carboplatin, cisplatin, pemtrexed BRCA1 VEGFA 2
pembrolizumab, guadecitabine, mocetinostat BRCA1 HDAC2 2
pembrolizumab, lenvatinib BRCA1 PDGFRA 2
pembrolizumab, lenvatinib BRCA1 KDR 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu BRCA1 PDGFRA 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu BRCA1 KDR 2
pembrolizumab, paclitaxel, docetaxel, irinotecan BRCA1 TOP1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BRCA1 PDGFRA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BRCA1 VEGFA 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BRCA1 RRM1 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin BRCA1 KDR 2
pemetrexed, bevacizumab BRCA1 VEGFA 2
pharmacological study, romidepsin BRCA1 HDAC2 2
ramucirumab, paclitaxel BRCA1 KDR 2
regorafenib, laboratory biomarker analysis BRCA1 PDGFRA 2
regorafenib, laboratory biomarker analysis BRCA1 KDR 2
rubitecan BRCA1 TOP1 2
sorafenib, administered orally, ct/mri BRCA1 FLT3 2
sorafenib, administered orally, ct/mri BRCA1 KDR 2
sy-5609, fulvestrant, gemcitabine, nab-paclitaxel BRCA1 RRM1 2
temsirolimus BRCA1 MTOR 2
temsirolimus, laboratory biomarker analysis BRCA1 MTOR 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy BRCA1 KDR 2
tucidinostat (chidamide), pd-1 inhibitor (toripalimab), bevacizumab BRCA1 VEGFA 2
axitinib BRCA1 KDR 7
ribociclib BRCA1 CDK6 7
ribociclib BRCA1 CDK4 7
romidepsin BRCA1 HDAC2 7
sorafenib BRCA1 FLT3 7
sorafenib BRCA1 KDR 7
trilaciclib BRCA1 CDK6 7
trilaciclib BRCA1 CDK4 7
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography BRCA1 PARP3 1
3-dimensional conformal radiation therapy, bevacizumab, cisplatin, fluorouracil, intensity-modulated radiation therapy BRCA1 VEGFA 1
3-dimensional conformal radiation therapy, bevacizumab, intensity-modulated radiation therapy, laboratory biomarker analysis, placebo, quality-of-life assessment, temozolomide BRCA1 VEGFA 1
3-dimensional conformal radiation therapy, cognitive assessment, laboratory biomarker analysis, temozolomide, vorinostat BRCA1 HDAC2 1
3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, laboratory biomarker analysis, vorinostat BRCA1 HDAC2 1
5 fluorouracil, leucovorin, irinotecan, oxaliplatin BRCA1 TOP1 1
5-fluorouracil (5-fu), leucovorin, oxaliplatin, atezolizumab, cobimetinib, ramucirumab, paclitaxel, pegylated recombinant human hyaluronidase (pegph20), bl-8040, linagliptin, atezolizumab, cobimetinib, cisplatin, tiragolumab, 5-fluorouracil (5-fu) BRCA1 KDR 1
9-ing-41, gemcitabine - 21 day cycle, doxorubicin., lomustine, carboplatin., nab paclitaxel., paclitaxel., gemcitabine - 28 day cycle, irinotecan BRCA1 TOP1 1
9-ing-41, retifanlimab, gemcitabine, abraxane BRCA1 RRM1 1
abemaciclib, abemaciclib BRCA1 CDK6 1
abemaciclib, abemaciclib BRCA1 CDK4 1
abemaciclib, bevacizumab BRCA1 VEGFA 1
abemaciclib, bevacizumab BRCA1 CDK6 1
abemaciclib, bevacizumab BRCA1 CDK4 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf BRCA1 TOP1 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf BRCA1 CDK6 1
abemaciclib, irinotecan, temozolomide, dinutuximab, gm-csf BRCA1 CDK4 1
abemaciclib, ly3023414, gemcitabine, capecitabine BRCA1 CDK6 1
abemaciclib, ly3023414, gemcitabine, capecitabine BRCA1 RRM1 1
abemaciclib, ly3023414, gemcitabine, capecitabine BRCA1 CDK4 1
abemaciclib, ly3214996 BRCA1 CDK6 1
abemaciclib, ly3214996 BRCA1 CDK4 1
abemaciclib, surgery BRCA1 CDK6 1
abemaciclib, surgery BRCA1 CDK4 1
abraxane (nab-paclitaxel), gemcitabine BRCA1 RRM1 1
acetazolamide, temozolomide BRCA1 CA3 1
acetazolamide, temozolomide BRCA1 CA1 1
adavosertib BRCA1 WEE1 1
adavosertib, laboratory biomarker analysis, pharmacological study, radiation therapy BRCA1 WEE1 1
adavosertib, radiation therapy, temozolomide BRCA1 WEE1 1
adct-601, gemcitabine BRCA1 RRM1 1
adjuvant therapy, temozolomide, valproic acid, radiation therapy BRCA1 HDAC2 1
adriamycin, cyclophosphamide, vindesine, valproic acid BRCA1 HDAC2 1
aee788, everolimus BRCA1 MTOR 1
aerosol sargramostim, sargramostim, cisplatin, doxorubicin hydrochloride, ifosfamide, mitomycin c, flow cytometry, immunological diagnostic method, laboratory biomarker analysis, adjuvant therapy, multimodality therapy, neoadjuvant therapy, therapeutic conventional surgery, intraoperative radiation therapy, selective external radiation therapy BRCA1 SDC2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BRCA1 PARP3 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BRCA1 CDK6 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BRCA1 MTOR 1
afatinib, dasatinib, palbociclib, everolimus, olaparib BRCA1 CDK4 1
afatinib, irinotecan BRCA1 TOP1 1
ag-013736, gemcitabine, gemcitabine, placebo BRCA1 RRM1 1
agen1423, botensilimab, gemcitabine, nab-paclitaxel BRCA1 RRM1 1
agent-797, botensilimab, balstilimab, ramucirumab, paclitaxel BRCA1 KDR 1
ags-1c4d4, gemcitabine BRCA1 RRM1 1
ak104, ak104, gemcitabine, nab-paclitaxel BRCA1 RRM1 1
ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, cadonilimab, nab-paclitaxel, gemcitabine, ak112, nab-paclitaxel, gemcitabine, nab-paclitaxel, gemcitabine BRCA1 RRM1 1
albumin-bound paclitaxel (abi-007), gemcitabine BRCA1 RRM1 1
aldesleukin, antibody therapy, fluorouracil, gemcitabine hydrochloride, irinotecan hydrochloride, laboratory biomarker analysis, leucovorin calcium, oxaliplatin, paclitaxel albumin-stabilized nanoparticle formulation, sargramostim BRCA1 SDC2 1
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation BRCA1 SDC2 1
aldesleukin, autologous tumor cell vaccine, muromonab-cd3, sargramostim, therapeutic autologous lymphocytes, surgical procedure, radiation therapy BRCA1 SDC2 1
aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes BRCA1 RRM1 1
aldoxorubicin, topotecan BRCA1 TOP1 1
alisertib BRCA1 AURKA 1
alisertib, gemcitabine BRCA1 RRM1 1
alisertib, gemcitabine BRCA1 AURKA 1
allogeneic tumor cell vaccine, recombinant interferon alfa, sargramostim, cyclophosphamide BRCA1 SDC2 1
alpelisib, everolimus, exemestane BRCA1 MTOR 1
alpelisib, everolimus, exemestane BRCA1 PIK3CA 1
alvocidib, docetaxel BRCA1 CDK6 1
alvocidib, docetaxel BRCA1 CDK2 1
alvocidib, docetaxel BRCA1 CDK4 1
alvocidib, docetaxel BRCA1 CDK5 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis BRCA1 CDK6 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis BRCA1 CDK2 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis BRCA1 CDK4 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis BRCA1 CDK5 1
amg 193, gemcitabine, nab-paclitaxel, modified folfirinox BRCA1 RRM1 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.